Evidence map›Paper›PMID 34164283›Full record

ReviewTranslational lung cancer research2021

The radiologist's role in lung cancer screening.

Annemiek Snoeckx, Caro Franck, Mario Silva, Mathias Prokop, Cornelia Schaefer-Prokop, Marie-Pierre Revel

Abstract readReview
In one paragraph

Review in Translational lung cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Current Evidence for a Lung Cancer Screening Program.Portuguese journal of public health · 2024
    Review
  8. Lung cancer screening: where do we stand?Breathe (Sheffield, England) · 2024
    Review
  9. Observational
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Annemiek SnoeckxDepartment of Radiology, Antwerp University Hospital and University of Antwerp, Edegem, Belgium.
Caro FranckDepartment of Radiology, Antwerp University Hospital and University of Antwerp, Edegem, Belgium.
Mario SilvaScienze Radiologiche, Department of Medicine and Surgery (DiMeC), University of Parma, Parma, Italy.
Mathias ProkopDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
Cornelia Schaefer-ProkopDepartment of Radiology, Meander Medical Center, Amersfoort, The Netherlands.
Marie-Pierre RevelDepartment of Radiology, Cochin Hospital, APHP Centre, Université de Paris, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is still the deadliest cancer in men and women worldwide. This high mortality is related to diagnosis in advanced stages, when curative treatment is no longer an option. Large randomized controlled trials have shown that lung cancer screening (LCS) with low-dose computed tomography (CT) can detect lung cancers at earlier stages and reduce lung cancer-specific mortality. The recent publication of the significant reduction of cancer-related mortality by 26% in the Dutch-Belgian NELSON LCS trial has increased the likelihood that implementation of LCS in Europe will move forward. Radiologists are important stakeholders in numerous aspects of the LCS pathway. Their role goes beyond nodule detection and nodule management. Being part of a multidisciplinary team, radiologists are key players in numerous aspects of implementation of a high quality LCS program. In this non-systematic review we discuss the multifaceted role of radiologists in LCS.

Indexed as

artificial intelligence (AI)imagingLung cancer screeningradiologistradiology

Identifiers

PMID34164283
PMCPMC8182709

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.